Abstract
Nearly 20 million people are diagnosed with cancer each year with breast cancer being the most common among women. Triple negative breast cancer (TNBC), defined by its no/low expression of ER and PR and lack of amplification of HER2, makes up 15–20% of all breast cancer cases. While patients overall have a higher response to chemotherapy, this subgroup is associated with the lowest survival rate indicating significant clinical and molecular heterogeneity demanding alternate treatment options. Therefore, new therapies have been explored, with a large focus on utilizing the immune system. A whole host of immunotherapies have been studied including immune checkpoint inhibitors, now standard of care for eligible patients, and possibly the most exciting and promising is that of a TNBC vaccine. While currently there are no approved TNBC vaccines, this review highlights many promising studies and points to an antigen, p53, which we believe is highly relevant for TNBC.
| Original language | English |
|---|---|
| Article number | 2472432 |
| Number of pages | 17 |
| Journal | Cancer Biology & Therapy |
| Volume | 26 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 15 Mar 2025 |
Keywords
- humans
- triple negative breast neoplasms/immunology
- cancer vaccines/therapeutic use
- female
- immunotherapy/methods
Access to Document
- The search for a TNBC vaccine: the guardian vaccine
Copyright 2025 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.